/
Rare Disease
Hemophilia a
41
Pipeline Programs↗
62
Active Trials↗
27
Companies Involved↗
Hemophilia A is a moderately active landscape with 41 programs across 27 companies. The most active players are Roche, Pfizer, Sanofi. 13 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical22
Phase 13
Phase 313
Approved
No programs
Analysis
Modality Breakdown
80%
Small molecule
24 of 30 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 30 classified programs, each share of the total. Modality classified for 98% of 41 pipeline programs.
Analysis
Trial Status
214
clinical trials
Completed115 · 54%
Recruiting28 · 13%
Active, not recruiting18 · 8%
Terminated18 · 8%
Not yet recruiting16 · 7%
Unknown status16 · 7%
Other3 · 1%
Clinical Trials
Trial Activity
214 trials
Page 1 of 15
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)